SCHEMBL22980773

SCHEMBL22980773

Cc1ccc(S(=O)(=O)n2ccc3ccc(NC(=O)O)cc32)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.58
CPT1A P50416 4/20 0.57
CPT2 P23786 3/20 0.57
CPT1B Q92523 3/20 0.53
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52
PPARG P37231 3/20 0.50
PPARD Q03181 2/20 0.50
PPARA Q07869 2/20 0.50
FABP4 P15090 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
DRD2 P14416 2/20 0.47
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC10 Q969S8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22074272 0.90 HTR6 (0.60) HTR6CPT1ACPT2CPT1BPPARG
SCHEMBL22980669 0.85 HTR6 (0.78) HTR6CPT1ACPT2CPT1BSLC1A3
SCHEMBL22990912 0.85 HTR6 (0.51) HTR6CPT1ACPT2CPT1BSLC1A3
SCHEMBL28933624 0.84 HTR6 (0.64) HTR6CPT1ACPT2CPT1BSLC1A3
SCHEMBL1898211 0.82 HTR6 (0.56) HTR6SLC1A3SLC1A2SLC1A1PPARG
SCHEMBL8652798 0.82 CPT1A (0.63) HTR6CPT1ACPT2CPT1BSLC1A3
SCHEMBL20742946 0.79 HTR6 (0.60) HTR6PPARGPPARDPPARAFABP4
SCHEMBL9372377 0.79 CPT1A (0.54) HTR6CPT1ACPT2CPT1BSLC1A3
SCHEMBL30955477 0.79 CPT1A (0.54) HTR6CPT1ACPT2CPT1BSLC1A3
SCHEMBL17049351 0.78 PPARG (0.53) HTR6CPT1ACPT2PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4010080-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-09-27 EP disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 US disclosed
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2022-09-22 US disclosed
EP-4010080-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2022-06-15 EP disclosed
WO-2021028643-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 HTR6 3126/4885CPT1A 209/4885CPT2 501/4885
US-20220298134-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 HTR6 3126/4885CPT1A 209/4885CPT2 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.